PFO
HURA

Pathstone Family Office’s TuHURA Biosciences HURA Stock Holding History

Pathstone Family Office’s Portfolio HURA Stock Details HURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11
Closed -$2.08K – 1608
2022
Q3 		$2.08K Buy
11
+5
+83% +$1.6K ﹤0.01% 1468
2022
Q2 		$2.78K Buy
+6
New +$2.61K ﹤0.01% 1047

Other funds holding HURA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Pathstone Family Office's HURA Position: Q4 2022 in Review

Pathstone Family Office sold out of TuHURA Biosciences (HURA) in Q4 2022, closing a stake of 11 shares — an estimated $2.08K sold.

Pathstone Family Office first reported a position in HURA in Q2 2022 and held it in 2 quarters. The position peaked at $2.78K in Q2 2022. 10 funds tracked by Wall St. Rank hold HURA as of Q4 2022.

  • Pathstone Family Office reported no remaining TuHURA Biosciences position as of Q4 2022 after selling out during the quarter.
  • Pathstone Family Office sold 11 TuHURA Biosciences shares in Q4 2022, an estimated $2.08K.
  • Pathstone Family Office first reported a position in TuHURA Biosciences in Q2 2022 and held it in 2 quarters.
  • Pathstone Family Office's TuHURA Biosciences position peaked at $2.78K in Q2 2022.
  • 10 funds tracked by Wall St. Rank held TuHURA Biosciences as of Q4 2022.

Based on Pathstone Family Office's 13F filing for Q4 2022, filed 13 Feb 2023.